Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Spero Therapeutics (SPRO) Receivables Refunds (2016 - 2022)

Spero Therapeutics (SPRO) has disclosed Receivables Refunds for 7 consecutive years, with $39000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Receivables Refunds fell 88.6% year-over-year to $39000.0, compared with a TTM value of $39000.0 through Sep 2022, down 88.6%, and an annual FY2021 reading of $361000.0, down 57.33% over the prior year.
  • Receivables Refunds was $39000.0 for Q3 2022 at Spero Therapeutics, up from $19000.0 in the prior quarter.
  • Across five years, Receivables Refunds topped out at $1.9 million in Q1 2018 and bottomed at $19000.0 in Q2 2022.
  • Average Receivables Refunds over 5 years is $766105.3, with a median of $786000.0 recorded in 2019.
  • Peak annual rise in Receivables Refunds hit 401.35% in 2022, while the deepest fall reached 94.51% in 2022.
  • Year by year, Receivables Refunds stood at $922000.0 in 2018, then dropped by 14.75% to $786000.0 in 2019, then rose by 7.63% to $846000.0 in 2020, then tumbled by 57.33% to $361000.0 in 2021, then crashed by 89.2% to $39000.0 in 2022.
  • Business Quant data shows Receivables Refunds for SPRO at $39000.0 in Q3 2022, $19000.0 in Q2 2022, and $371000.0 in Q1 2022.